期刊
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
卷 9, 期 9, 页码 1211-1223出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17512433.2016.1200463
关键词
Celiac disease; refractory celiac disease; glutenase; tight junction regulators; larazotide; gluten free diet
资金
- Alba Therapeutics
- Alvine Pharmaceuticals
- INOVA Diagnostics
- Genzyme
- Coronado Biosciences
- Sidney Frank Foundation
- Pfizer
Introduction: A gluten free diet (GFD) is the only available treatment for celiac disease (CD). However many patients fail to respond fully clinically or histologically. Several surveys highlight the psychosocial implications of adherence to a GFD. Hence, efforts are ongoing to develop therapeutic strategies beyond a GFD.Areas covered: We conducted a search of PubMed and clinicaltrials.gov to extract articles on CD using keywords including celiac disease' and refractory celiac disease' (RCD) and focused on articles conducting pathophysiologic and therapeutic research in/ex-vivo models and human trials. We highlight novel therapeutics that manipulate these mechanisms including tight junction regulators, glutenases, gluten sequestrants and immunotherapy using vaccines, nanoparticles that may serve as adjuncts to a GFD or more ambitiously to allow for gluten consumption. We also highlight the role of anti-inflammatories, immunosuppressants and monoclonal antibodies in RCD.Expert commentary: Therapeutics including tight junction regulators, glutenases have the potential to be approved for non-responsive CD or as gluten adjuncts. We expect results of various phase 1/2 trials using AMG 714, BL 7010, IgY antibodies to be published. In the interim, off-label use of 5 amino-salicylates, budesonide, nucleoside analogues and newer biologics developed for other inflammatory diseases will be used in RCD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据